Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Travis A. Clark, Jon H. Chung, Mark Kennedy, Jason D. Hughes, Niru Chennagiri, Daniel S. Lieber, Bernard Fendler, Lauren Young, Mandy Zhao, Michael Coyne, Virginia Breese, Geneva Young, Amy Donahue, Dean Pavlick, Alyssa Tsiros, Timothy Brennan, Shan Zhong, Tariq Mughal, Mark Bailey, Jie HeSteven Roels, Garrett M. Frampton, Jill M. Spoerke, Steven Gendreau, Mark Lackner, Erica Schleifman, Eric Peters, Jeffrey S. Ross, Siraj M. Ali, Vincent A. Miller, Jeffrey Gregg, Philip J. Stephens, Allison Welsh, Geoff A. Otto, Doron Lipson

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Genomic profiling of circulating tumor DNA derived from cell-free DNA (cfDNA) in blood can provide a noninvasive method for detecting genomic biomarkers to guide clinical decision making for cancer patients. We developed a hybrid capture–based next-generation sequencing assay for genomic profiling of circulating tumor DNA from blood (FoundationACT). High-sequencing coverage and molecular barcode–based error detection enabled accurate detection of genomic alterations, including short variants (base substitutions, short insertions/deletions) and genomic re-arrangements at low allele frequencies (AFs), and copy number amplifications. Analytical validation was performed on 2666 reference alterations. The assay achieved >99% overall sensitivity (95% CI, 99.1%–99.4%) for short variants at AF >0.5%, >95% sensitivity (95% CI, 94.2%–95.7%) for AF 0.25% to 0.5%, and 70% sensitivity (95% CI, 68.2%–71.5%) for AF 0.125% to 0.25%. No false positives were detected in 62 samples from healthy volunteers. Genomic alterations detected by FoundationACT demonstrated high concordance with orthogonal assays run on the same clinical cfDNA samples. In 860 routine clinical FoundationACT cases, genomic alterations were detected in cfDNA at comparable frequencies to tissue; for the subset of cases with temporally matched tissue and blood samples, 75% of genomic alterations and 83% of short variant mutations detected in tissue were also detected in cfDNA. On the basis of analytical validation results, FoundationACT has been approved for use in our Clinical Laboratory Improvement Amendments–certified/College of American Pathologists–accredited/New York State–approved laboratory.

Original languageEnglish (US)
Pages (from-to)686-702
Number of pages17
JournalJournal of Molecular Diagnostics
Volume20
Issue number5
DOIs
StatePublished - Sep 1 2018

Fingerprint

Circulating Neoplastic Cells
Gene Frequency
DNA
Neoplasms
Healthy Volunteers
Biomarkers
Mutation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine

Cite this

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. / Clark, Travis A.; Chung, Jon H.; Kennedy, Mark; Hughes, Jason D.; Chennagiri, Niru; Lieber, Daniel S.; Fendler, Bernard; Young, Lauren; Zhao, Mandy; Coyne, Michael; Breese, Virginia; Young, Geneva; Donahue, Amy; Pavlick, Dean; Tsiros, Alyssa; Brennan, Timothy; Zhong, Shan; Mughal, Tariq; Bailey, Mark; He, Jie; Roels, Steven; Frampton, Garrett M.; Spoerke, Jill M.; Gendreau, Steven; Lackner, Mark; Schleifman, Erica; Peters, Eric; Ross, Jeffrey S.; Ali, Siraj M.; Miller, Vincent A.; Gregg, Jeffrey; Stephens, Philip J.; Welsh, Allison; Otto, Geoff A.; Lipson, Doron.

In: Journal of Molecular Diagnostics, Vol. 20, No. 5, 01.09.2018, p. 686-702.

Research output: Contribution to journalArticle

Clark, TA, Chung, JH, Kennedy, M, Hughes, JD, Chennagiri, N, Lieber, DS, Fendler, B, Young, L, Zhao, M, Coyne, M, Breese, V, Young, G, Donahue, A, Pavlick, D, Tsiros, A, Brennan, T, Zhong, S, Mughal, T, Bailey, M, He, J, Roels, S, Frampton, GM, Spoerke, JM, Gendreau, S, Lackner, M, Schleifman, E, Peters, E, Ross, JS, Ali, SM, Miller, VA, Gregg, J, Stephens, PJ, Welsh, A, Otto, GA & Lipson, D 2018, 'Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA', Journal of Molecular Diagnostics, vol. 20, no. 5, pp. 686-702. https://doi.org/10.1016/j.jmoldx.2018.05.004
Clark, Travis A. ; Chung, Jon H. ; Kennedy, Mark ; Hughes, Jason D. ; Chennagiri, Niru ; Lieber, Daniel S. ; Fendler, Bernard ; Young, Lauren ; Zhao, Mandy ; Coyne, Michael ; Breese, Virginia ; Young, Geneva ; Donahue, Amy ; Pavlick, Dean ; Tsiros, Alyssa ; Brennan, Timothy ; Zhong, Shan ; Mughal, Tariq ; Bailey, Mark ; He, Jie ; Roels, Steven ; Frampton, Garrett M. ; Spoerke, Jill M. ; Gendreau, Steven ; Lackner, Mark ; Schleifman, Erica ; Peters, Eric ; Ross, Jeffrey S. ; Ali, Siraj M. ; Miller, Vincent A. ; Gregg, Jeffrey ; Stephens, Philip J. ; Welsh, Allison ; Otto, Geoff A. ; Lipson, Doron. / Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. In: Journal of Molecular Diagnostics. 2018 ; Vol. 20, No. 5. pp. 686-702.
@article{f86e6bfaa22e4ff2bf9b76bddedcc6b7,
title = "Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA",
abstract = "Genomic profiling of circulating tumor DNA derived from cell-free DNA (cfDNA) in blood can provide a noninvasive method for detecting genomic biomarkers to guide clinical decision making for cancer patients. We developed a hybrid capture–based next-generation sequencing assay for genomic profiling of circulating tumor DNA from blood (FoundationACT). High-sequencing coverage and molecular barcode–based error detection enabled accurate detection of genomic alterations, including short variants (base substitutions, short insertions/deletions) and genomic re-arrangements at low allele frequencies (AFs), and copy number amplifications. Analytical validation was performed on 2666 reference alterations. The assay achieved >99{\%} overall sensitivity (95{\%} CI, 99.1{\%}–99.4{\%}) for short variants at AF >0.5{\%}, >95{\%} sensitivity (95{\%} CI, 94.2{\%}–95.7{\%}) for AF 0.25{\%} to 0.5{\%}, and 70{\%} sensitivity (95{\%} CI, 68.2{\%}–71.5{\%}) for AF 0.125{\%} to 0.25{\%}. No false positives were detected in 62 samples from healthy volunteers. Genomic alterations detected by FoundationACT demonstrated high concordance with orthogonal assays run on the same clinical cfDNA samples. In 860 routine clinical FoundationACT cases, genomic alterations were detected in cfDNA at comparable frequencies to tissue; for the subset of cases with temporally matched tissue and blood samples, 75{\%} of genomic alterations and 83{\%} of short variant mutations detected in tissue were also detected in cfDNA. On the basis of analytical validation results, FoundationACT has been approved for use in our Clinical Laboratory Improvement Amendments–certified/College of American Pathologists–accredited/New York State–approved laboratory.",
author = "Clark, {Travis A.} and Chung, {Jon H.} and Mark Kennedy and Hughes, {Jason D.} and Niru Chennagiri and Lieber, {Daniel S.} and Bernard Fendler and Lauren Young and Mandy Zhao and Michael Coyne and Virginia Breese and Geneva Young and Amy Donahue and Dean Pavlick and Alyssa Tsiros and Timothy Brennan and Shan Zhong and Tariq Mughal and Mark Bailey and Jie He and Steven Roels and Frampton, {Garrett M.} and Spoerke, {Jill M.} and Steven Gendreau and Mark Lackner and Erica Schleifman and Eric Peters and Ross, {Jeffrey S.} and Ali, {Siraj M.} and Miller, {Vincent A.} and Jeffrey Gregg and Stephens, {Philip J.} and Allison Welsh and Otto, {Geoff A.} and Doron Lipson",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.jmoldx.2018.05.004",
language = "English (US)",
volume = "20",
pages = "686--702",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "5",

}

TY - JOUR

T1 - Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

AU - Clark, Travis A.

AU - Chung, Jon H.

AU - Kennedy, Mark

AU - Hughes, Jason D.

AU - Chennagiri, Niru

AU - Lieber, Daniel S.

AU - Fendler, Bernard

AU - Young, Lauren

AU - Zhao, Mandy

AU - Coyne, Michael

AU - Breese, Virginia

AU - Young, Geneva

AU - Donahue, Amy

AU - Pavlick, Dean

AU - Tsiros, Alyssa

AU - Brennan, Timothy

AU - Zhong, Shan

AU - Mughal, Tariq

AU - Bailey, Mark

AU - He, Jie

AU - Roels, Steven

AU - Frampton, Garrett M.

AU - Spoerke, Jill M.

AU - Gendreau, Steven

AU - Lackner, Mark

AU - Schleifman, Erica

AU - Peters, Eric

AU - Ross, Jeffrey S.

AU - Ali, Siraj M.

AU - Miller, Vincent A.

AU - Gregg, Jeffrey

AU - Stephens, Philip J.

AU - Welsh, Allison

AU - Otto, Geoff A.

AU - Lipson, Doron

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Genomic profiling of circulating tumor DNA derived from cell-free DNA (cfDNA) in blood can provide a noninvasive method for detecting genomic biomarkers to guide clinical decision making for cancer patients. We developed a hybrid capture–based next-generation sequencing assay for genomic profiling of circulating tumor DNA from blood (FoundationACT). High-sequencing coverage and molecular barcode–based error detection enabled accurate detection of genomic alterations, including short variants (base substitutions, short insertions/deletions) and genomic re-arrangements at low allele frequencies (AFs), and copy number amplifications. Analytical validation was performed on 2666 reference alterations. The assay achieved >99% overall sensitivity (95% CI, 99.1%–99.4%) for short variants at AF >0.5%, >95% sensitivity (95% CI, 94.2%–95.7%) for AF 0.25% to 0.5%, and 70% sensitivity (95% CI, 68.2%–71.5%) for AF 0.125% to 0.25%. No false positives were detected in 62 samples from healthy volunteers. Genomic alterations detected by FoundationACT demonstrated high concordance with orthogonal assays run on the same clinical cfDNA samples. In 860 routine clinical FoundationACT cases, genomic alterations were detected in cfDNA at comparable frequencies to tissue; for the subset of cases with temporally matched tissue and blood samples, 75% of genomic alterations and 83% of short variant mutations detected in tissue were also detected in cfDNA. On the basis of analytical validation results, FoundationACT has been approved for use in our Clinical Laboratory Improvement Amendments–certified/College of American Pathologists–accredited/New York State–approved laboratory.

AB - Genomic profiling of circulating tumor DNA derived from cell-free DNA (cfDNA) in blood can provide a noninvasive method for detecting genomic biomarkers to guide clinical decision making for cancer patients. We developed a hybrid capture–based next-generation sequencing assay for genomic profiling of circulating tumor DNA from blood (FoundationACT). High-sequencing coverage and molecular barcode–based error detection enabled accurate detection of genomic alterations, including short variants (base substitutions, short insertions/deletions) and genomic re-arrangements at low allele frequencies (AFs), and copy number amplifications. Analytical validation was performed on 2666 reference alterations. The assay achieved >99% overall sensitivity (95% CI, 99.1%–99.4%) for short variants at AF >0.5%, >95% sensitivity (95% CI, 94.2%–95.7%) for AF 0.25% to 0.5%, and 70% sensitivity (95% CI, 68.2%–71.5%) for AF 0.125% to 0.25%. No false positives were detected in 62 samples from healthy volunteers. Genomic alterations detected by FoundationACT demonstrated high concordance with orthogonal assays run on the same clinical cfDNA samples. In 860 routine clinical FoundationACT cases, genomic alterations were detected in cfDNA at comparable frequencies to tissue; for the subset of cases with temporally matched tissue and blood samples, 75% of genomic alterations and 83% of short variant mutations detected in tissue were also detected in cfDNA. On the basis of analytical validation results, FoundationACT has been approved for use in our Clinical Laboratory Improvement Amendments–certified/College of American Pathologists–accredited/New York State–approved laboratory.

UR - http://www.scopus.com/inward/record.url?scp=85051635969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051635969&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2018.05.004

DO - 10.1016/j.jmoldx.2018.05.004

M3 - Article

C2 - 29936259

AN - SCOPUS:85051635969

VL - 20

SP - 686

EP - 702

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 5

ER -